Biogen enlists Royalty for pursuit of lupus crown, securing $250M to fund phase 3 program

Biogen has bagged $250 million to advance a key pipeline prospect. Royalty Pharma is providing the cash to bankroll phase 3 development of a lupus candidate that Biogen has named in a bunch of assets with potential peak sales of $14 billion.